Sodium-glucose cotransporter-2 inhibitors and kidney outcomes in real-world type 2 diabetes populations: A systematic review and meta-analysis of observational studies.
Anna K ForbesRebecca J SucklingWilliam HintonMichael D FeherDebasish BanerjeeNicholas I ColeSimon de LusignanPauline A SwiftPublished in: Diabetes, obesity & metabolism (2023)
The reno-protective benefits of SGLT2 inhibitors apply to a broad population of adults with T2D treated in routine clinical practice, including those at lower risk of kidney events with normal eGFR and without albuminuria. These findings support the early use of SGLT2 inhibitors in T2D for preservation of kidney health.